Grünenthal Group: First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist
The trial explores how the NOP agonist influences pain signalling and perception using laser evoked potentials (LEPs) in an experimental pain model with 30 healthy participants. On five different occasions, the participants will receive either the NOP agonist or pregabalin or placebo. The trial explores three different doses of the NOP agonist; pregabalin and placebo will be given to ensure control conditions. In the experimental pain model, a laser will generate a short tolerable painful heat stimulus on the participant’s skin which has been sensitised to mimic a temporary state of neuropathic pain. Both objective and subjective endpoints will be assessed in response to the laser stimuli, including electroencephalography (EEG) to measure brain activity and the Visual Analogue Scale (VAS) for subjective pain perception.
”This peripherally restricted, potent and selective NOP receptor agonist has shown analgesic effects in a wide range of pre-clinical pain models[1],” says Jan Adams, M.D., Chief Scientific Officer Grünenthal. “Millions of patients suffer from chronic neuropathic pain and are in need of better treatment options. With its unique mechanism of action, our NOP agonist may have the potential to provide these patients with a therapeutic benefit and an improved safety profile compared to the available standards of care.”
A First-in-Human clinical trial to assess the safety and tolerability profile and the pharmacokinetic characteristics of the NOP agonist is ongoing since December 2020. In addition, Grünenthal intends to start a Phase IIa trial to evaluate the compound’s efficacy in patients with painful diabetic peripheral neuropathy in 2022.
Grünenthal’s R&D pipeline includes multiple programmes across different targets, modalities and mechanisms of action to deliver better treatments for patients with severe pain conditions. In addition to developing its NOP agonist, Grünenthal is conducting a Phase I clinical trial with a Glucocorticoid Receptor Modulator (GRM) aiming to provide patients with a therapy option for chronic inflammatory diseases. Grünenthal recently announced the start of recruitment for a Phase III clinical trial with Qutenza® (capsaicin) 8% topical system in post-surgical neuropathic pain. In addition, Grünenthal intends to enrol the first patients with painful osteoarthritis of the knee in a Phase III clinical trial to investigate the efficacy, safety and tolerability of Resiniferatoxin by Q1 2022.
[1] Grünenthal Data on file
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
For further information, please contact:
Christopher Jansen, Communication Business Partner
Phone: +49 241 569-1428
Christopher.Jansen@grunenthal.com
Florian Dieckmann, Head Global Communications
Phone: +49 241 569-2555
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Intuitive Surgical Deutschland GmbH: Intuitive’s da Vinci 5 Surgical System Receives CE Mark2.7.2025 09:55:29 CEST | Press release
Fifth-generation da Vinci surgical system approved for use in Europe across multiple procedures
EUROJET signs contract to provide EJ200 Engines for the recent Italian Air Force Eurofighter Order of up to 24 Aircraft27.6.2025 16:25:57 CEST | Press release
Rome, Italy, Friday, 27th June 2025 EUROJET Turbo GmbH, the consortium behind the EJ200 engine that powers the Eurofighter Typhoon, has today signed a new contract with the NATO Eurofighter & Tornado Management Agency (NETMA). Under this agreement, EUROJET will deliver up to 54 new EJ200 engines to the Italian Air Force as part of the Eurofighter Tranche I replacement. A renaissance of interest in the programme, it follows hot on the heels of the Spanish Halcón II contract announced at the end of last year.
European Marketing Distribution: MANIELE TASCA TAKES OVER PRESIDENCY OF EUROPE'S LEADING TRADE ALLIANCE EMD27.6.2025 08:30:00 CEST | Press release
Top manager from Italy emphasises continued close partnership with industry Stephanie Lotter, Director at Globus in Germany, elected to the EMD Executive Board
Invest Taicang: The 17th Taicang Day in Stuttgart Celebrates Over 30 Years of Sino-German Cooperation and Innovation26.6.2025 08:41:11 CEST | Press release
On June 25, the 17th "Taicang Day" event kicked off in Stuttgart, marking a significant milestone in the longstanding relationship between Taicang, a city in E China, and Germany. The event returned to its original location in the heart of the "Motor City," where nearly 300 guests, including officials from the Baden-Württemberg state government, the Ministry of Economic Affairs, the Stuttgart government, the German Chamber of Commerce, renowned trade and investment promotion organizations, and executives from German companies, gathered to discuss new opportunities for Sino-German cooperation. Hosted by the Taicang municipal government, this year's theme, "Innovation-Driven, Green Win-Win," highlighted Taicang's deepening ties with Germany across various sectors, including trade, education, culture, and sustainability. The event was a platform for fostering continued collaboration between both nations, with key discussions on shared innovation and sustainable development. In his opening
EMD's Retail Group further consolidates its position with Axfood from Sweden / The international retail alliance EMD is continuing to expand its importance in the cooperation with the A-brand industry25.6.2025 08:30:00 CEST | Pressemelding
Pfäffikon/Switzerland, 13/06/2025: By effectively combining forces to benefit its millions of retail customers, European Marketing Distribution (EMD) has risen to the top of the international trade alliances with this formula. The latest example of this successful strategy is the integration of the Swedish Axfood Group, an EMD member since 1995, which will join the EMD Retail Group in 2026. To clarify: while EMD and its member companies focus on the procurement and marketing of successful private label products, EMD members united in the Retail Group also implement cross-border services and marketing concepts in partnership with leading multinational A-brand manufacturers.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom